Erick Gamelin
Corporate Officer/Principal at ACRIVON THERAPEUTICS, INC.
Net worth: 137 146 $ as of 2024-05-30
Network origin in Erick Gamelin first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Unknown | 18 | ||
| Public Company | Biotechnology | 7 | |
| Public Company | Pharmaceuticals: Major | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Erick Gamelin via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ABIOMED, INC. | Medical Specialties | Director of Finance/CFO | |
| ALBEMARLE CORPORATION | Chemicals: Specialty | Investor Relations Contact | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| IMMUNOMEDICS, INC. | Biotechnology | Director/Board Member | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Human Resources Officer Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| DYAX CORP. | Pharmaceuticals: Major | Chief Administrative Officer | |
| AGENUS INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| RIGEL PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Investor Relations Contact | |
| ARRAY TECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member | |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Analyst-Equity | |
| MILESTONE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
Metamark Genetics, Inc.
 Metamark Genetics, Inc. Medical/Nursing ServicesHealth Services Metamark Genetics, Inc. provides molecular diagnostics services. It develops prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients. It transforms cancer diagnosis and treatment by developing pioneering diagnostic products based on its prognosis determinants platform. The company was founded by Kenneth E. Weg, Raju S. Kucherlapati, David Rimm, Lynda Chin and Ronald A. DePinho in November 2007 and is headquartered in Waltham, MA. | Medical/Nursing Services | Chief Operating Officer Corporate Officer/Principal | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree | |
| College of the Holy Cross (Massachusetts) | College/University | Undergraduate Degree | |
| MIRATI THERAPEUTICS | Biotechnology | Chief Executive Officer | |
| Boston College | College/University | Undergraduate Degree | |
| Princeton University | College/University | Undergraduate Degree | |
| University of Wisconsin | College/University | Undergraduate Degree | |
| University of California, Davis | College/University | Doctorate Degree | |
Optimer Pharmaceuticals LLC
 Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Pharmaceuticals: Major | Director/Board Member | |
The Ruth Group, Inc.
 The Ruth Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Ruth Group provides investor relations and public relations services. The comapny's services include communications services targeting the financial community from pre-IPO services through financial communications, analyst relations and shareholder monitoring. It also serves public and private companies by offering media relations, training and trade show support services. The company was founded in 1999 by Carol Ruth and is located in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| University of Lund | College/University | Doctorate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
| University of Strasbourg | College/University | Doctorate Degree | |
General Electric Healthcare Technologies, Inc.
 General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Medical/Nursing Services | Corporate Officer/Principal | |
| EMD Serono Research & Development Institute, Inc. | Corporate Officer/Principal | ||
The Lexington
 The Lexington Medical/Nursing ServicesHealth Services Part of The Ensign Group, Inc., The Lexington operates a 125-bed assisted living facility. The company is based in Ventura, CA. | Medical/Nursing Services | Director of Finance/CFO | |
| Motorola Automotive & Industrial Electronics Group | Corporate Officer/Principal | ||
Ropes & Gray LLP
 Ropes & Gray LLP Miscellaneous Commercial ServicesCommercial Services Ropes & Gray LLP provides legal and private equity services. Its practice areas include asset management, banking, business and commercial litigation, business restructuring, capital markets and corporate governance and compliance. The company was founded in 1865 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| The IGB Group | President | ||
| Boston College Law School | College/University | Graduate Degree | |
| Washington University School of Medicine | College/University | Doctorate Degree | |
| CRISPR THERAPEUTICS AG | Biotechnology | Director of Finance/CFO | |
| PMV PHARMACEUTICALS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
| POSEIDA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
| 89BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Packaged Software | Chairman | |
| ONCTERNAL THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor | |
Canbridge Pharmaceuticals, Inc. (United States)
 Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Biotechnology | Director/Board Member | |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | Packaged Software | Director/Board Member | |
| BUTTERFLY NETWORK, INC. | Medical Specialties | General Counsel | |
Cimeio Therapeutics AG
 Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Packaged Software | Director/Board Member | |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
| ZAI LAB LIMITED | Biotechnology | Corporate Officer/Principal |
Statistics
International
| United States | 42 |
| Switzerland | 3 |
| Canada | 2 |
| Sweden | 2 |
| Denmark | 2 |
Sectoral
| Health Technology | 23 |
| Consumer Services | 12 |
| Technology Services | 5 |
| Finance | 4 |
| Health Services | 4 |
Operational
| Director/Board Member | 61 |
| Corporate Officer/Principal | 43 |
| Independent Dir/Board Member | 29 |
| Undergraduate Degree | 15 |
| Doctorate Degree | 13 |
Most connected contacts
| Insiders | |
|---|---|
| Andrew Hack | 20 |
| Ivana Magovcevic-Liebisch | 18 |
| Derek DiRocco | 17 |
| Michael Tomsicek | 12 |
| Charles Baum | 12 |
| Eddie J. Gray | 10 |
| Jeff P. Coon | 10 |
| Stanley Plotkin | 9 |
| Adam Levy | 8 |
| Mary Miller | 8 |
| Jay Siegel | 8 |
| Peter Blume-Jensen | 8 |
| Eric Devroe | 8 |
| David Burke | 5 |
| Rajesh Krishnan | 5 |
- Stock Market
- Insiders
- Erick Gamelin
- Company connections
